<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35585442</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1435-4373</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>18</Day>
            </PubDate>
          </JournalIssue>
          <Title>European journal of clinical microbiology &amp; infectious diseases : official publication of the European Society of Clinical Microbiology</Title>
          <ISOAbbreviation>Eur J Clin Microbiol Infect Dis</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Antimicrobial resistance among Haemophilus influenzae isolates responsible for lower respiratory tract infections in Poland, 2005-2019.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s10096-022-04457-w</ELocationID>
        <Abstract>
          <AbstractText>Haemophilus influenzae is a human-specific pathogen responsible for respiratory tract infections, meningitis, and sepsis. The study aimed to characterize antibiotic resistance in H. influenzae strains isolated from patients with lower respiratory tract infections over 15 years in Poland. The minimum inhibitory concentrations (MICs) of clinically relevant antibiotics were determined by broth microdilution method. Screening for beta-lactam resistance was performed in all isolates following EUCAST recommendation. Finally, relevant changes in penicillin-binding protein 3 (PBP3) were detected by PCR screening. Of the 1481 isolates collected between 2005 and 2019, 12.6%, 0.2%, 17.1%, and 0.2% were resistant to ampicillin, amoxicillin/clavulanate, cefuroxime, and ceftriaxone, respectively. Among them, 74.4% (1102/1481) of isolates were categorized as BLNAS (β-lactamase negative, ampicillin-susceptible), 13.0% (192/1481) as BLNAS with modified PBP3 (mutations in ftsI gene), 2.6% (39/1481) as BLNAR (β-lactamase negative, ampicillin-resistant), and 0.2% had PBP3 modifications typical for high-BLNAR. Production of β-lactamase characterized 9.7% of isolates (8.6% BLPAR-β-lactamase-positive, ampicillin-resistant, and 1.1% BLPACR-β-lactamase-positive, amoxicillin-clavulanate resistant). Three isolates with PBP3 modifications typical for high-BLNAR proved resistant to ceftriaxone (MIC &gt; 0.125 mg/L). Resistance to ciprofloxacin, chloramphenicol, tetracycline, and trimethoprim-sulfamethoxazole was observed in 0.1%, 0.5%, 1.6%, and 24.7% of isolates, respectively. This is the first report of Polish H. influenzae isolates resistant to third-generation cephalosporins. Polish H. influenzae isolates demonstrate similar susceptibility trends as in many other countries. The substantial proportion of β-lactam-resistant isolates and the emergence of those resistant to third-generation cephalosporins are of great concern and should be under surveillance.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Kiedrowska</LastName>
            <ForeName>Marlena</ForeName>
            <Initials>M</Initials>
            <Identifier Source="ORCID">0000-0003-2318-3375</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland. m.kiedrowska@nil.gov.pl.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Foryś</LastName>
            <ForeName>Weronika Jasmina</ForeName>
            <Initials>WJ</Initials>
            <Identifier Source="ORCID">0000-0002-2704-6186</Identifier>
            <AffiliationInfo>
              <Affiliation>Bachelor of Liberal Arts Program, Harvard University, Boston, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gołębiewska</LastName>
            <ForeName>Agnieszka</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-9662-8243</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Waśko</LastName>
            <ForeName>Izabela</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0001-5494-3635</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Biomedical Research, National Medicines Institute, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ronkiewicz</LastName>
            <ForeName>Patrycja</ForeName>
            <Initials>P</Initials>
            <Identifier Source="ORCID">0000-0003-4427-5076</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuch</LastName>
            <ForeName>Alicja</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0001-5416-1422</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wróbel-Pawelczyk</LastName>
            <ForeName>Izabela</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0002-4726-5984</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wroczyński</LastName>
            <ForeName>Michał</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Faculty of Agriculture and Biology, Warsaw University of Life Sciences, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hryniewicz</LastName>
            <ForeName>Waleria</ForeName>
            <Initials>W</Initials>
            <Identifier Source="ORCID">0000-0002-3651-9790</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Skoczyńska</LastName>
            <ForeName>Anna</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-2247-830X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Epidemiology and Clinical Microbiology, National Medicines Institute, Chełmska 30/34, 00-725, Warsaw, Poland.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>18</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Germany</Country>
        <MedlineTA>Eur J Clin Microbiol Infect Dis</MedlineTA>
        <NlmUniqueID>8804297</NlmUniqueID>
        <ISSNLinking>0934-9723</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">BLNAR</Keyword>
        <Keyword MajorTopicYN="N">BLPACR</Keyword>
        <Keyword MajorTopicYN="N">BLPAR</Keyword>
        <Keyword MajorTopicYN="N">Haemophilus influenzae</Keyword>
        <Keyword MajorTopicYN="N">Resistance</Keyword>
        <Keyword MajorTopicYN="N">Susceptibility</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>23</Hour>
          <Minute>34</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35585442</ArticleId>
        <ArticleId IdType="doi">10.1007/s10096-022-04457-w</ArticleId>
        <ArticleId IdType="pii">10.1007/s10096-022-04457-w</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Tsang RSW, Ulanova M (2017) The changing epidemiology of invasive Haemophilus influenzae disease: emergence and global presence of serotype a strains that may require a new vaccine for control. Vaccine 35:4270–4275. https://doi.org/10.1016/j.vaccine.2017.06.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2017.06.001</ArticleId>
            <ArticleId IdType="pubmed">28666758</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Su PY, Huang AH, Lai CH, Lin HF, Lin TM, Ho CH (2020) Extensively drug-resistant Haemophilus influenzae – emergence, epidemiology, risk factors, and regimen. BMC Microbiol 20:102. https://doi.org/10.1186/s12866-020-01785-9</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12866-020-01785-9</ArticleId>
            <ArticleId IdType="pubmed">32345232</ArticleId>
            <ArticleId IdType="pmc">7189504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Murphy TF (2015) Haemophilus species, including H. influenzae and H. ducreyi (Chancroid). In: Bennett JE, Dolin R, Blaser MJ Principles and Practice of infectious diseases, 8<sup>th</sup> edn. Philadelphia, PA, pp 2575–2578</Citation>
        </Reference>
        <Reference>
          <Citation>(2017) Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections, including tuberculosis. World Health Organization. https://www.who.int/medicines/areas/rational_use/PPLreport_2017_09_19.pdf . Accessed 17 January 2022</Citation>
        </Reference>
        <Reference>
          <Citation>Jakubu V, Malisova L, Musilek M, Pomorska K, Zemlickova H (2021) Characterization of Haemophilus influenzae strains with non-enzymatic resistance to β-lactam antibiotics caused by mutations in the PBP3 gene in the Czech Republic in 2010–2018. Life (Basel) 11(11):1260. https://doi.org/10.3390/life11111260</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/life11111260</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giufrè M, Cardines R, Caporali MG, Accogli M, D’Ancona F, Cerquetti M (2011) Ten years of Hib vaccination in Italy: prevalence of non-encapsulated Haemophilus influenzae among invasive isolates and the possible impact on antibiotic resistance. Vaccine 29(22):3857–3862. https://doi.org/10.1016/j.vaccine.2011.03.059</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2011.03.059</ArticleId>
            <ArticleId IdType="pubmed">21459175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giufrè M, Daprai L, Cardines R, Bernaschi P, Ravà L, Accogli M, Raponi M, Garlaschi ML, CiofidegliAtti ML, Cerquetti M (2015) Carriage of Haemophilus influenzae in the oropharynx of young children and molecular epidemiology of the isolates after fifteen years of H influenzae type b vaccination in Italy. Vaccine 33(46):6227–34. https://doi.org/10.1016/j.vaccine.2015.09.082</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2015.09.082</ArticleId>
            <ArticleId IdType="pubmed">26440924</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giufrè M, Fabiani M, Cardines R, Riccardo F, Caporali MG, D’Ancona F, Pezzotti P, Cerquetti M (2018) Increasing trend in invasive non-typeable Haemophilus influenzae disease and molecular characterization of the isolates, Italy, 2012–2016. Vaccine 36(45):6615–6622. https://doi.org/10.1016/j.vaccine.2018.09.060</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.09.060</ArticleId>
            <ArticleId IdType="pubmed">30292458</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tsang RSW, Shuel M, Whyte K et al (2017) Antibiotic susceptibility and molecular analysis of invasive Haemophilus influenzae in Canada, 2007 to 2014. J Antimicrob Chemother 72(5):1314–1319. https://doi.org/10.1093/jac/dkw565</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkw565</ArticleId>
            <ArticleId IdType="pubmed">28137937</ArticleId>
            <ArticleId IdType="pmc">5890693</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Medeiros AA, O’Brien TF (1975) Ampicillin-resistant Haemophilus influenzae type B possessing a TEM-type beta-lactamase but little permeability barrier to ampicillin. Lancet 1:716–719. https://doi.org/10.1016/s0140-6736(75)91630-x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(75)91630-x</ArticleId>
            <ArticleId IdType="pubmed">47483</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markowitz SM (1980) Isolation of an ampicillin-resistant, non-beta-lactamase-producing strain of Haemophilus influenzae. Antimicrob Agents Chemother 17(1):80–83. https://doi.org/10.1128/AAC.17.1.80</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.17.1.80</ArticleId>
            <ArticleId IdType="pubmed">6965443</ArticleId>
            <ArticleId IdType="pmc">283729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tristram S, Jacobs MR, Appelbaum PC (2007) Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev 20:368–389. https://doi.org/10.1128/CMR.00040-06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/CMR.00040-06</ArticleId>
            <ArticleId IdType="pubmed">17428889</ArticleId>
            <ArticleId IdType="pmc">1865592</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ubukata K, Shibasaki Y, Yamamoto K, Chiba N, Hasegawa K, Takeuchi Y, Sunakawa K, Inoue M, Konno M (2001) Association of amino acid substitutions in penicillin-binding protein 3 with beta-lactam resistance in beta-lactamase-negative ampicillin-resistant Haemophilus influenzae. Antimicrob Agents Chemother 45:1693–1699. https://doi.org/10.1128/AAC.45.6.1693-1699.2001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.45.6.1693-1699.2001</ArticleId>
            <ArticleId IdType="pubmed">11353613</ArticleId>
            <ArticleId IdType="pmc">90533</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Honda H, Sato T, Shinagawa M et al (2018) Multiclonal expansion and high prevalence of β-lactamase-negative Haemophilus influenzae with high-level ampicillin resistance in japan and susceptibility to quinolones. Antimicrob Agents Chemother. 62(9):1–18. https://doi.org/10.1128/AAC.00851-18</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00851-18</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heliodoro CIM, Bettencourt CR, Bajanca-Lavado MP; Portuguese Group for the Study of Haemophilus influenzae invasive infection (2020) Molecular epidemiology of invasive Haemophilus influenzae disease in Portugal: an update of the post-vaccine period, 2011–2018. Eur J Clin Microbiol Infect Dis 39(8):1471–1480. https://doi.org/10.1007/s10096-020-03865-0</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10096-020-03865-0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skoczyńska A, Kadłubowski M, Waśko I, Fiett J, Hryniewicz W (2007) Resistance patterns of selected respiratory tract pathogens in Poland. Clin Microbiol Infect 13:377–383. https://doi.org/10.1111/j.1469-0691.2007.01664.x</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1469-0691.2007.01664.x</ArticleId>
            <ArticleId IdType="pubmed">17359321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kiedrowska M, Kuch A, Żabicka D, Waśko I, Ronkiewicz P, Wasiak K, Bojarska K, Hryniewicz W, Skoczyńska A (2017) β-Lactam resistance among Haemophilus influenzae isolates in Poland. J Glob Antimicrob Resist 11:161–166. https://doi.org/10.1016/j.jgar.2017.08.005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jgar.2017.08.005</ArticleId>
            <ArticleId IdType="pubmed">28818575</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barbosa AR, Giufrè M, Cerquetti M, Bajanca-Lavado MP (2011) Polymorphism in ftsI gene and {beta}-lactam susceptibility in Portuguese Haemophilus influenzae strains: clonal dissemination of beta-lactamase-positive isolates with decreased susceptibility to amoxicillin/clavulanic acid. J Antimicrob Chemother 66:788–796. https://doi.org/10.1093/jac/dkq533</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkq533</ArticleId>
            <ArticleId IdType="pubmed">21393206</ArticleId>
            <ArticleId IdType="pmc">3058566</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lâm TT, Claus H, Elias J, Frosch M, Vogel U (2015) Ampicillin resistance of invasive Haemophilus influenzae isolates in Germany 2009–2012. Int J Med Microbiol 305:748–755. https://doi.org/10.1016/j.ijmm.2015.08.028</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijmm.2015.08.028</ArticleId>
            <ArticleId IdType="pubmed">26321008</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Deghmane AE, Hong E, Chehboub S, Terrade A, Falguières M, Sort M, Harrison O, Jolley KA, Taha MK 2019 High diversity of invasive Haemophilus influenzae isolates in France and the emergence of resistance to third generation cephalosporins by alteration of ftsI gene. J Infect 79:7–14. 1016/j.jinf.2019.05.007</Citation>
        </Reference>
        <Reference>
          <Citation>Schotte L, Wautier M, Martiny D, Piérard D, Depypere M (2019) Detection of beta-lactamase-negative ampicillin resistance in Haemophilus influenzae in Belgium. Diagn Microbiol Infect Dis 93(3):243–249. https://doi.org/10.1016/j.diagmicrobio.2018.10.009</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diagmicrobio.2018.10.009</ArticleId>
            <ArticleId IdType="pubmed">30424950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>European Committee on Antimicrobial Susceptibility Testing (EUCAST). (Version 11.0. 2021) Breakpoint tables for interpretations of MICs and zone diameters: 60–65. https://www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Breakpoint_tables/v_11.0_Breakpoint_Tables.pdf .</Citation>
        </Reference>
        <Reference>
          <Citation>Hasegawa K, Yamamoto K, Chiba N et al (2003) Diversity of ampicillin-resistance genes in Haemophilus influenzae in Japan and the United States. Microb Drug Resist 9(1):39–46. https://doi.org/10.1089/107662903764736337</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/107662903764736337</ArticleId>
            <ArticleId IdType="pubmed">12705682</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hobson RP, Williams A, Rawal K, Pennington TH, Forbes KJ (1995) Incidence and spread of Haemophilus influenzae on an Antarctic base determined using the polymerase chain reaction. Epidemiol Infect 114:93–103. https://doi.org/10.1017/s0950268800051943</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/s0950268800051943</ArticleId>
            <ArticleId IdType="pubmed">7867747</ArticleId>
            <ArticleId IdType="pmc">2271340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Meats E, Feil EJ, Stringer S et al (2003) Characterization of encapsulated and noncapsulated Haemophilus influenzae and determination of phylogenetic relationships by multilocus sequence typing. J Clin Microbiol 41(4):1623–1636. https://doi.org/10.1128/JCM.41.4.1623-1636.2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JCM.41.4.1623-1636.2003</ArticleId>
            <ArticleId IdType="pubmed">12682154</ArticleId>
            <ArticleId IdType="pmc">153921</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Osaki Y, Sanbongi Y, Ishikawa M et al (2005) Genetic approach to study the relationship between penicillin-binding protein 3 mutations and Haemophilus influenzae beta-lactam resistance by using site-directed mutagenesis and gene recombinants. Antimicrob Agents Chemother 49(7):2834–2839. https://doi.org/10.1128/AAC.49.7.2834-2839.2005</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.49.7.2834-2839.2005</ArticleId>
            <ArticleId IdType="pubmed">15980357</ArticleId>
            <ArticleId IdType="pmc">1168665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skaare D, Anthonisen IL, Kahlmeter G, Matuschek E, Natås OB, Steinbakk M, Sundsfjord A, Kristiansen BE (2014) Emergence of clonally related multidrug resistant Haemophilus influenzae with penicillin-binding protein 3-mediated resistance to extended-spectrum cephalosporins, Norway, 2006 to 2013. Euro Surveill 19:20986. https://doi.org/10.2807/1560-7917.es2014.19.49.20986</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2807/1560-7917.es2014.19.49.20986</ArticleId>
            <ArticleId IdType="pubmed">25523969</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yamada S, Seyama S, Wajima T, Yuzawa Y, Saito M, Tanaka E, Noguchi N (2020) β-Lactamase-non-producing ampicillin-resistant Haemophilus influenzae is acquiring multidrug resistance. J Infect Public Health 13(4):497–501. https://doi.org/10.1016/j.jiph.2019.11.003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiph.2019.11.003</ArticleId>
            <ArticleId IdType="pubmed">31839585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cerquetti M, Cardines R, Giufrè M, Mastrantonio P, Hi Study Group (2004) Antimicrobial susceptibility of Haemophilus influenzae strains isolated from invasive disease in Italy. J Antimicrob Chemother 54(6):1139–1143. https://doi.org/10.1093/jac/dkh467</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkh467</ArticleId>
            <ArticleId IdType="pubmed">15486078</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sanbongi Y, Suzuki T, Osaki Y, Senju N, Ida T, Ubukata K (2006) Molecular evolution of beta-lactam-resistant Haemophilus influenzae: 9-year surveillance of penicillin-binding protein 3 mutations in isolates from Japan. Antimicrob Agents Chemother 50:2487–2492. https://doi.org/10.1128/AAC.01316-05</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01316-05</ArticleId>
            <ArticleId IdType="pubmed">16801430</ArticleId>
            <ArticleId IdType="pmc">1489784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>García-Cobos S, Campos J, Lázaro E, Román F, Cercenado E, García-Rey C, Pérez-Vázquez M, Oteo J, de Abajo F (2007) Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 51:2564–2573. https://doi.org/10.1128/AAC.00354-07</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00354-07</ArticleId>
            <ArticleId IdType="pubmed">17470649</ArticleId>
            <ArticleId IdType="pmc">1913223</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhanel GG, Palatnick L, Nichol KA, Low DE, Hoban DJ (2003) CROSS Study Group. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob Agents Chemother 47:1875–1881. https://doi.org/10.1128/aac.47.6.1875-1881.2003</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/aac.47.6.1875-1881.2003</ArticleId>
            <ArticleId IdType="pubmed">12760861</ArticleId>
            <ArticleId IdType="pmc">155833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mizoguchi A, Hitomi S (2019) Cefotaxime-non-susceptibility of Haemophilus influenzae induced by additional amino acid substitutions of G555E and Y557H in altered penicillin-binding protein 3. J Infect Chemother 25:509–513. https://doi.org/10.1016/j.jiac.2019.02.010</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jiac.2019.02.010</ArticleId>
            <ArticleId IdType="pubmed">30879978</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aguirre-Quiñonero A, Pérez Del Molino IC, de la Fuente CG, Sanjuán MC, Agüero J, Martínez-Martínez L (2018) Phenotypic detection of clinical isolates of Haemophilus influenzae with altered penicillin-binding protein 3. Eur J Clin Microbiol Infect Dis 37:1475–1480. https://doi.org/10.1007/s10096-018-3273-z</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10096-018-3273-z</ArticleId>
            <ArticleId IdType="pubmed">29756174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barriere SL, Hindler JA (1993) Ciprofloxacin-resistant Haemophilus influenzae infection in a patient with chronic lung disease. Ann Pharmacother 27(3):309–310. https://doi.org/10.1177/106002809302700311</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/106002809302700311</ArticleId>
            <ArticleId IdType="pubmed">8453168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuo SC, Chen PC, Shiau YR, Wang HY, Lai JF 1st, Huang W, Lauderdale TL (2014) Levofloxacin-resistant Haemophilus influenzae, Taiwan, 2004–2010. Emerg Infect Dis 20:1386–1390. https://doi.org/10.3201/eid2008.140341</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3201/eid2008.140341</ArticleId>
            <ArticleId IdType="pubmed">25061696</ArticleId>
            <ArticleId IdType="pmc">4111205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-Vázquez M, Román F, García-Cobos S, Campos J (2007) Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability. Antimicrob Agents Chemother 51:1566–1569. https://doi.org/10.1128/AAC.01437-06</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01437-06</ArticleId>
            <ArticleId IdType="pubmed">17283196</ArticleId>
            <ArticleId IdType="pmc">1855460</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-Vázquez M, Román F, Varela MC, Cantón R, Campos J (2003) Activities of 13 quinolones by three susceptibility testing methods against a collection of Haemophilus influenzae isolates with different levels of susceptibility to ciprofloxacin: evidence for cross-resistance. J Antimicrob Chemother 51(1):147–151. https://doi.org/10.1093/jac/dkg049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkg049</ArticleId>
            <ArticleId IdType="pubmed">12493800</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Biedenbach DJ, Jones RN (2003) Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program. Diagn Microbiol Infect Dis 46:55–61. https://doi.org/10.1016/s0732-8893(03)00016-6</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0732-8893(03)00016-6</ArticleId>
            <ArticleId IdType="pubmed">12742320</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pérez-Trallero E, Martín-Herrero JE, Mazón A, García-Delafuente C, Robles P, Iriarte V, Dal-Ré R, García-de-Lomas J (2010) Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial resistance among respiratory pathogens in Spain: latest data and changes over 11 years (1996–1997 to 2006–2007). Antimicrob Agents Chemother 54:2953–2959. https://doi.org/10.1128/AAC.01548-09</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.01548-09</ArticleId>
            <ArticleId IdType="pubmed">20439616</ArticleId>
            <ArticleId IdType="pmc">2897302</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Puig C, Tirado-Vélez JM, Calatayud L, Tubau F, Garmendia J, Ardanuy C, Marti S, de la Campa AG, Liñares J (2015) Molecular characterization of fluoroquinolone resistance in nontypeable Haemophilus influenzae clinical isolates. Antimicrob Agents Chemother 59:461–466. https://doi.org/10.1128/AAC.04005-14</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.04005-14</ArticleId>
            <ArticleId IdType="pubmed">25385097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirakata Y, Ohmori K, Mikuriya M, Saika T, Matsuzaki K, Hasegawa M, Hatta M, Yamamoto N, Kunishima H, Yano H, Kitagawa M, Arai K, Kawakami K, Kobayashi I, Jones RN, Kohno S, Yamaguchi K, Kaku M (2009) Antimicrobial activities of piperacillin-tazobactam against Haemophilus influenzae isolates, including beta-lactamase-negative ampicillin-resistant and beta-lactamase-positive amoxicillin-clavulanate-resistant isolates, and mutations in their quinolone resistance-determining regions. Antimicrob Agents Chemother 53:4225–4230. https://doi.org/10.1128/AAC.00192-09</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.00192-09</ArticleId>
            <ArticleId IdType="pubmed">19651910</ArticleId>
            <ArticleId IdType="pmc">2764172</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
